+260 (211) 222288
admin@pmslzambia.co.zm
Premium House,
P.O. Box 35177, Lusaka
08:00 - 17:00
Monday to Saturday
+260 (211) 226469
admin@pmslzambia.co.zm
Elizabetha Villa,
Plot 110A Chishango Road
08:00 - 17:00
Monday to Saturday
We have over 25 years of experience.
admin@pmslzambia.co.zm
P.O. Box 35177, Lusaka
Monday to Saturday
admin@pmslzambia.co.zm
Plot 110A Chishango Road
Monday to Saturday
By WHO
Category: Health, Industry
No Comments
New US$50 billion health, trade and finance roadmap to end the pandemic and secure a global recovery. The heads of the world’s predominant global financing, health and trade agencies have united to urge government leaders to urgently finance a new US$50 billion roadmap to accelerate the equitable distribution of health tools to help end the pandemic that has devastated lives and livelihoods for 18 months and also set the foundations for a truly global recovery, as well as enhanced health security.
Read More
By Xinua
Category: Health, Industry
No Comments
Zambia on Wednesday launched the COVID-19 vaccination program against the pandemic.
The national launch, which was held at the University Teaching Hospital (UTH), the country's highest referral hospital in the country's capital Lusaka, was attended by officials from the health ministry, cooperating partners and private sector representatives.
The launch involves the first pillar of the program under the COVAX Facility consisting of 228,000 doses of AstraZeneca manufactured in India.
The first pillar will cover 20 percent or 3.6 million of the eligible over 18 years people and will target front-line health workers and other people at most risk. A total of 8.3 million people are targeted to be vaccinated..
By Daily Mail Zambia
Category: Healthc, Industry
No Comments
AFRICA, now more than before, needs robust health care systems to keep its populations healthy and productive in the face of COVID-19.
President Edgar Lungu is on point in calling for African leaders to focus on building their respective countries’ health care capacities by training more health workers in various specialities to keep the continent’s population productive.As the President has noted, with Africa’s population growing to almost 1.4 billion, leaders on the continent should prioritise strengthening their health care systems.
He urges “African leaders and all of you to focus on building our health care capacity and train more and more health care providers in various specialties to keep the African population healthy and productive.”Needless to say, Africa needs a healthy and productive population to push its development agenda. And at a time that Africa is battling with the COVID-19 pandemic, the continent cannot afford to lag behind in terms of health care capacity.
By WHO
Category: Health, Industry
No Comments
WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations. WHO today validated the Sinovac-CoronaVac COVID-19 vaccine for emergency use, giving countries, funders, procuring agencies and communities the assurance that it meets international standards for safety, efficacy and manufacturing. The vaccine is produced by the Beijing-based pharmaceutical company Sinovac.
“The world desperately needs multiple COVID-19 vaccines to address the huge access inequity across the globe,” said Dr Mariângela Simão, WHO Assistant-Director General for Access to Health Products. “We urge manufacturers to participate in the COVAX Facility, share their knowhow and data and contribute to bringing the pandemic under control.”
WHO’s Emergency Use Listing (EUL) is a prerequisite for COVAX Facility vaccine supply and international procurement. It also allows countries to expedite their own regulatory approval to import and administer COVID-19 vaccines.
The EUL assesses the quality, safety and efficacy of COVID-19 vaccines, as well as risk management plans and programmatic suitability, such as cold chain requirements. The assessment is performed by the product evaluation group, composed by regulatory experts from around the world and a Technical Advisory Group (TAG), in charge of performing the risk-benefit assessment for an independent recommendation on whether a vaccine can be listed for emergency use and, if so, under which conditions.
November 21, 2019
November 21, 2020
November 21, 2021
Should you have any queries, please feel free to contact Premium Medical Services.
Contact Us